Clinical trial of levodopa combined with entacapone in the treatment of Parkinson’ s disease
10.13699/j.cnki.1001-6821.2016.14.012
- VernacularTitle:左旋多巴联合恩他卡朋治疗帕金森病的临床研究
- Author:
Gong-Ling WEN
1
;
Chang-Ming WEN
;
Yan-Ping WANG
;
Mei-Juan KANG
;
Jing ZHOU
;
Yi-Feng LIU
;
Bao-Chao ZHANG
Author Information
1. 南阳市中心医院 神经内科
- Keywords:
levodopa;
entacapone;
Parkinson’s disease;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(14):1289-1292
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of levodopa combined with entacapone in the treatment of Parkinson ’ s di-sease.Methods Fifty -four patients with Parkinson ’ s disease were randomly divided into treatment group(n=27) and control group(n=27). Control group was given levodopa 0.25 g oral, tid.Treatment group was treated with entacapone 0.2 g oral tid, on the basis of the control group . Two groups were treated for 16 weeks.The clinical efficacy , serum levels of interleukin(IL) -1β, IL-6, malonaldehyde, superoxide dismutase ( SOD) and glutathione peroxidase ( GSH-Px) , scores of unified Parkin-son’ s disease rating scale ( UPDRS) and incidence of adverse drug reac-tions were compared between two groups .Results After treatment , the total effective rate of treatment group was significantly higher than that of control group (92.59%vs 70.37%, P<0.05).After treatment, among the treatment and control group , the levels of serum IL -1βwere (32.32 ±0.32), (45.35 ±6.01)pg? L -1, IL-6 were (4.03 ±0.54), (6.78 ±0.82)pg? L-1, malonaldehyde were (14.72 ±2.21), (19.37 ±2.44)mmol? mg -1, UPDRS-Ⅱscore were (3.98 ±1.56), (11.74 ±1.25) point and UPDRS-Ⅲscore were (26.43 ±3.28), (31.54 ±4.17) point, and those indexes in treatment group after treat-ment were significantly lower than those of control group ( P<0.05 ) .After treatment , the levels of serum SOD were (135.55 ±17.84), (120.93 ±18.38)U? μg-1 and GSH-Px were (99.74 ±12.43), (90.73 ±10.84)U? μg-1 in treatment and control group , also the those indexes in treatment group after treatment were significantly higher than those in control group ( P<0.05 ).The adverse drug reactions were based on the symptoms of nervous system , diges-tive system and skin for two groups.Also, the incidence of adverse drug reactions in control group was 14.81%, treat-ment group was 11.11%, the difference had no statistically significant difference ( P>0.05 ).Conclusion Levodopa combined with entacapone have a definitive clinical efficacy for the treatment of Parkinson ’ s disease , without increasing the incidence of adverse drug reactions .
